Injective (INJ) is on a technical tear. The token has surged above all major moving averages, and one widely watched forecast now puts its price at $6.20 within the next 30 days — a move that would mark a fresh leg up from current levels. The Relative Strength Index (RSI) sits at 68, comfortably in bullish territory but not yet overbought.
What the technicals are saying
The $6.20 target comes from a projection based on current chart patterns and momentum indicators. INJ's climb has been broad-based: it's now trading above its 50-day, 100-day, and 200-day moving averages, a configuration traders often call a 'golden cross' stack. The RSI reading of 68 suggests buyers remain in control, though a reading above 70 would signal the asset is entering overbought conditions.
The bullish case is straightforward: as long as INJ holds above key support levels, the upward trend should continue. The next major resistance to watch is the $6.20 area, which aligns with the projected target.
The level that could break the rally
Not everything is a straight line up. The forecast hinges on INJ maintaining its footing above $4.97. If that support level fails to hold, the entire bullish thesis would be invalidated. A break below $4.97 would expose the token to a potential retest of lower support zones, possibly around $4.50 or below.
That's the risk baked into the current setup: momentum is strong, but it's not guaranteed. Traders are watching that $4.97 level like a hawk. Any daily close under it would likely trigger stop-losses and shift sentiment from bullish to neutral or bearish.
What happens next
The next 30 days will be the test. If INJ can push through the $6.20 target, the next upside targets will come into focus. If it fails at support, the rally is over for now. Either way, the market will have its answer soon enough.
